OraSure Technologies Commends New York State Hepatitis C Testing Law
23 Ottobre 2013 - 7:10PM
OraSure Technologies, Inc. (Nasdaq:OSUR) applauds New York State's
new hepatitis C (HCV) testing law, which requires providers in all
clinical settings in the state of New York (except emergency rooms)
to offer a one-time HCV test to individuals born between 1945
and 1965. Governor Andrew Cuomo signed the bill into law today and
it will take effect as of January 1, 2014.
According to the Centers for Disease Control and Prevention
(CDC), HCV is the most common chronic blood-borne infection in the
United States. Up to 75 percent of people with hepatitis C are
unaware of their infection. It is estimated that Baby Boomers
(adults born between 1945 and 1965) are five times more likely to
have hepatitis C than other adults. The CDC recommends that all
Baby Boomers, approximately 78.2 million individuals, be tested for
hepatitis C at least once.
"We applaud New York State on its new hepatitis C testing law,
and for its leadership in taking action to fight the hepatitis C
epidemic," said Douglas A. Michels, President and Chief Executive
Officer of OraSure Technologies. "As a result of this new law, we
believe more individuals at risk for HCV will get tested and learn
their hepatitis C status. With the use of our OraQuick® Rapid HCV
test, individuals presumed to be infected can be referred
immediately for follow-up care."
The OraQuick® HCV Rapid Antibody Test is the first and only
FDA-approved, CLIA-waived rapid, point-of-care test for the
detection of antibodies to the hepatitis C virus. OraQuick® HCV
results are available in 20 minutes, which can help increase the
delivery of test results, allowing early diagnosis and linkage to
care, treatment and prevention services, particularly for those at
risk for hepatitis C.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture
and distribution of oral fluid diagnostic and collection devices
and other technologies designed to detect or diagnose critical
medical conditions. Its innovative products include rapid tests for
the detection of antibodies to HIV and HCV at the point of care and
testing solutions for detecting various drugs of abuse. In July
2012, the Company received approval from the U.S. Food and Drug
Administration for the Company's OraQuick® In-Home HIV Test for
sale directly to consumers in the over-the-counter (OTC) market -
making it the first and only rapid OTC HIV test approved in the
U.S. In addition, the Company is a leading provider of oral fluid
sample collection, stabilization and preparation products for
molecular diagnostic applications. OraSure's portfolio of products
is sold globally to various clinical laboratories, hospitals,
clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors,
government agencies, physicians' offices, and commercial and
industrial entities. The Company's products enable healthcare
providers to deliver critical information to patients, empowering
them to make decisions to improve and protect their health.
For more information on OraSure Technologies, please visit
www.orasure.com.
CONTACT: Media Contact:
Jennifer Moritz
Zer0 to 5ive for OraSure Technologies
917-748-4006
jmoritz@0to5.com
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Ott 2023 a Ott 2024